期刊文献+

维格列汀有关物质检查

Study on Determination of the Related Substances in Vildagliptin
下载PDF
导出
摘要 建立了测定维格列汀有关物质检查方法。用十八烷基硅烷键合硅胶为填充剂,以磷酸盐缓冲液(取磷酸氢二铵2.64 g,溶于1000 m L水中,用稀氨水或磷酸溶液调节p H值至8.0±0.05)-甲醇(90∶10)为流动相A,甲醇为流动相B;进行梯度洗脱。流速1.0 m L·min-1,柱温40℃,检测波长210 nm。对维格列汀3种杂质进行定量检查。结果表明:各杂质与主成分能完全分离,杂质Ⅰ、Ⅱ、Ⅲ检测限分别为1.1、1.2、1.2 ng(S/N=3),回收率分别为96.8%、103.6%、107.1%,浓度与峰面积均呈线性(r>0.999)。结论本法准确、简便、快速,可用于维格列汀有关物质检查。 A method for determination of the related substances in Vildagliptin was established. It was determined on HPLC. The C18 was used as analytical column. Phosphate buffer (containing 2.46 g of diammonium hydrogen phosphate in 1 litre of water, adjusted to pH 8.0±0. 05 with ammonium hydroxide solution or phosphoric acid) and methanol (90 : 10) were used as mobile phases A, methanol were used as mobile phases B, with gradient elution. The column temperature was kept at 40 ℃. The flow rate was 1.0 mL · min^-1. The detection wavelength was set at 210 nm. Results showed that Vildagliptin and its impurities could be separated with all related substances completely. The limits of detection was 1.1, 1.2, 1.2 ng ( S/N = 3 ) for impurity Ⅰ , Ⅱ , Ⅲ. Their linearities were good, with their recoveries 96.8%, 103.6%, 107.1%, respectively. The method is accurate and sensitive, and can be used for the related substances in Vildagliptin.
作者 杨梅 陈红
出处 《广州化工》 CAS 2016年第16期149-151,共3页 GuangZhou Chemical Industry
关键词 维格列汀 有关物质 维格列汀杂质Ⅰ、Ⅱ、Ⅲ Vildagliptin related substance Vildagliptin impurity Ⅰ , Ⅱ , Ⅲ
  • 相关文献

参考文献5

二级参考文献63

  • 1许小聪,刘美华,卢彦兵,徐伟箭.N,N′-羰基二咪唑作为活化剂在高分子合成中的研究进展[J].高分子通报,2007(2):74-80. 被引量:15
  • 2夏玲红.治疗糖尿病的新药西他列汀[J].中国新药杂志,2007,16(12):979-981. 被引量:26
  • 3PRATLEY RE, SALSALI A, MATFIN G. Inhibition of dipeptidyl peptidase-4 with vildagliptin : a potential new treatment for type 2 diabetes[ J]. Br J Diabetes Vasc Dis,2006,6(4) : 150 - 156.
  • 4VILLHAUER EB, BRINKMAN JA, NADERI GB, et al. 1-[ [ ( 3- hydroxy-1 - adamantyl ) amino ] acetyl ] -2-cyano-( S ) - pyrrolidine : a potent, selective, and orally bioavailable dipeptidyl peptidase Ⅳ inhibitor with antihyperglycemic properties[ J ]. J Med Chem, 2003,46 ( 13 ) :2774 - 2789.
  • 5MARGUET D, BAGGIO L,KOBAYASHI,et al. Enhanced insulin secretion and inproved glucose tolerance in mice lacking CD26 [ J ]. Proc Natl Acad Sci USA ,2000,97 ( 12 ) :6874 - 6879.
  • 6NAGAKUBA T, YASUDA N,YAMAZAKI K,et al. Improved glucose tolerance via enhanced glucose-dependent insulin secretion in dipeptldyl peptidase Ⅳ- deficient Fischer rats [ J ]. Biochem Biophys Res Commun,2001,284(2 ) :501 - 506.
  • 7HE Y,BALCH A, CAMPESTRINI J, et al. Pharmacokinetics and pharmacodynamics of the DPP-4 inhibitor, LAF237, in patients with type 2 diabetes [ J ]. Clin Pharmacol Ther,2005,77 ( 2 ) :56.
  • 8HE YL,SABO R,CAMPESTRINI J ,et al. The influence of hepatic impairment on the pharmacokinetics of the dipeptidyl peptidase Ⅳ ( DDP-4 ) inhibitor vildagliptin [ J ]. Eur J. Clin Pharm,2007, 63(7) :677 -686.
  • 9PRATLEY RE, JAUFFRET-KAMEL S, GALBREATH E,et al. Twelve-week monotherapy with the DPP-4 inhibitor vildagliptin improves glycemic control in subjects with type 2 diabetes [ J ]. Horm Metab Res ,2006,38 ( 6 ) :423 - 428.
  • 10RISTIC S, BYIERS S, FOLEY J,et al. Improved glycaemic control with dipeptidyl peptidase-4 inhibition in patients with type 2 diabetes: vildagliptin ( LAF237 ) dose response [ J ]. Diabetes Obes Metab,2005,7 ( 6 ) : 692 - 698.

共引文献52

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部